Anti-CD4 activity of normal human immunoglobulin G for therapeutic use. (Intravenous immunoglobulin, IVIg).
The effects of intravenously administered normal immunoglobulin G (IVIg) in autoimmune diseases are dependent on the ability of IVIg to interact with surface molecules of lymphocytes. In the present study, we demonstrate the presence of anti-CD4 activity in IVIg by showing the ability of IVIg to bind to CD4 and to inhibit CD4-dependent cellular functions. Binding of IVIg to recombinant soluble human CD4 was assessed by ELISA, immunoblotting and real time analysis of complex formation. Anti-CD4 antibodies isolated from IVIg by affinity-chromatography bound to human CD4+ T cells. These anti-CD4 antibodies inhibited proliferative responses in MLR and infection of CD4+ human T cells with HIV. These results indicate that IVIg contains antibodies reactive with human CD4 and that these anti-CD4 antibodies exhibit biological functions. The presence of anti-CD4 antibodies in IVIg may be relevant to the immunoregulatory effects of normal polyspecific immunoglobulin G.
Hurez
V
V
INSERM U 28, Hôpital Broussais, Paris, France.
Kaveri
S V
SV
Mouhoub
A
A
Dietrich
G
G
Mani
J C
JC
Klatzmann
D
D
Kazatchkine
M D
MD
D000276:Adjuvants, Immunologic; D015153:Blotting, Western; D015704:CD4 Antigens / Q000276:immunology*; D019085:Fluorescent Antibody Technique, Direct; D015658:HIV Infections / Q000276:immunology; D015497:HIV-1 / Q000254:growth & development; D006801:Humans; D007118:Immunoassay; D016756:Immunoglobulins, Intravenous / Q000276:immunology*; D007959:Lymphocyte Culture Test, Mixed; D011485:Protein Binding
D000276:Adjuvants, Immunologic; D015704:CD4 Antigens; D016756:Immunoglobulins, Intravenous